 The study involves the addition of transdermal 100mcg estradiol or transdermal placebo- inactive substance to standard antipsychotic treatment for 4 weeks. The length of the trial is 1 menstrual cycle, which is a short period of estrogen use. Most side effects commonly associated with estrogen use are related to long term administration and are thus not applicable in this study. 